Biomarkers of the Dementia

Table 1

Eleven major studies of CSF biomarkers for AD published between 1998 and 2009.

Study	year	subjects	biomarker	sensitivity	specificity	other
Kanai	1998	93 AD, 54 cont, 33 nAD, 56 ND	Aβ40, Aβ42, ^†Tau	71~91%	83%	Multicenter, prospective
Hulstaert	1999	150 AD, 100 cont, 79 nAD, 84 ND	Aβ42, ^†Tau	85%	86%	10 European center
Knopman	2001	3 Class II, III studies	Aβ42, ^†Tau	80~97%	86~95%	System review AAN
Andreasen	2001	163 AD, 23 VaD, 20 MCI, 9 DLB, 8 ND,; 18 cont	Aβ42, ^†Tau	75~94%	89~100%	1 Y-prospective
Itoh	2001	236 AD, 239 nAD/ND, 95 cont,	PTau199	85%	85%	multicenter
Shoji	2002	366 AD, 181 cont,; 168 nAD, 316 ND	^†Tau	59%	90%	multicenter
Clark	2003	106 dementia, 73 cont	Aβ42, ^†Tau	85%	84%	2~8 Y follow up autopsy confirmed
Sunderland	2003	17Aβ42 studies, 34 tau studies; (3133 AD versus 1481 control)	Aβ42, ^†Tau	92%	89%	Meta-analysis
Blennow	2003	41Tau studies; (2500 AD versus 1400 cont); 15Aβ42 studies; (600 AD versus 450 cont); 11p-Tau studies; (800 AD versus 370 cont)	Aβ42,; ^†Tau,; PTau; Aβ42/tTau	86%; 90%; 92%; 85~94%	90%; 81%; 80%; 83~100%	Systematic review; Early AD, MCI
Hampel	2004	161 AD/FTD/DLB/VaD, 45 cont	PTau231; pTau181; pTau199	85%	83%,; 79%,; 60~71%	International harmonization
GTT3	2004	243 AD, 91 cont, 152 nAD, 157 ND	Aβ40, Aβ42, ^†Tau	80%	84%	Continuous GTT1